Dyne Therapeutics, Inc. DYN
General analysis — not personal advice.
The Q2 2026 BLA timeline is a high-impact catalyst warranting a position/tactics review ahead of regulatory milestones, while risks (regulatory and signaling from insider sales) have increased.
This picture changes. Follow Dyne Therapeutics, Inc. free — email when the signal or risk changes + a Sunday weekly brief.
Follow Dyne Therapeutics, Inc. freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Price & valuation
Market sentiment
Why NEUTRAL?
- Review exposure ahead of the Q2 2026 BLA window; avoid aggressively adding until there is more clarity on regulatory process/acceptance and insider-selling dynamics.
Recent News
- On July 29, 2026, Dyne Therapeutics reported its financial results for the second quarter of 2026. The U.S. FDA accepted for Priority Review the company's Biologics License Application for z-rostudirsen with a PDUFA target action date set for January 21, 2027. Dyne also completed a public offering in July 2026 that generated approximately $405 million in net proceeds.
Catalysts
z-rostudirsen (DMD) BLA submission planned in Q2 2026
What Firelda Watch includes for Dyne Therapeutics, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — AI roundup of the week's news
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Own Dyne Therapeutics, Inc.? Create a free account and follow up to 3 companies — change history, weekly brief, and email when the picture changes. Upgrade to Watch for more slots and same-day alerts.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more